Beta-Blockers in Pregnancy: Clinical Update.

IF 3.9 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Hypertension Reports Pub Date : 2023-02-01 DOI:10.1007/s11906-023-01234-8

Vasiliki Katsi, Ilias P Papakonstantinou, Ourania Papazachou, Thomas Makris, Konstantinos Tsioufis

{"title":"Beta-Blockers in Pregnancy: Clinical Update.","authors":"Vasiliki Katsi, Ilias P Papakonstantinou, Ourania Papazachou, Thomas Makris, Konstantinos Tsioufis","doi":"10.1007/s11906-023-01234-8","DOIUrl":null,"url":null,"abstract":"Purpose of review: The aim of this review was to determine the anticipated benefits and adverse effects of beta-blockers in pregnant women with hypertension. The other issue was to assess the possible adverse effects of beta-blockers for their babies and provide current consensus recommendations for appropriate selection and individualized antihypertensive treatment with beta-blockers in pregnancy-associated hypertension.Recent findings: Hypertensive disorders of pregnancy are a major cause of maternal and fetal morbidity, with consequences later in life. Certain beta-blockers are useful for ameliorating hypertension in pregnancy and may have a protective role in endothelial dysfunction. However, some aspects of beta-blocker use in pregnancy are contentious among providers. Evidence on their safety, although well documented, is variable, and recent research reveals areas of controversy. Besides intrauterine growth restriction, other neonatal and obstetric complications remain a concern and should be explored thoroughly. Attention is necessary when treating pregnancy-associated hypertensive disorders with beta-blockers. Specific beta-blockers are considered safe in pregnancy, although the associated effects in the fetus are not clearly known and evidence is lacking for many safety outcomes, other than intrauterine growth restriction. Nevertheless, beta-blockers with specific indications in pregnancy under individualized selection and monitoring may confer substantial improvements in pregnant women with hypertension.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"25 2","pages":"13-24"},"PeriodicalIF":3.9000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hypertension Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11906-023-01234-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose of review: The aim of this review was to determine the anticipated benefits and adverse effects of beta-blockers in pregnant women with hypertension. The other issue was to assess the possible adverse effects of beta-blockers for their babies and provide current consensus recommendations for appropriate selection and individualized antihypertensive treatment with beta-blockers in pregnancy-associated hypertension.

Recent findings: Hypertensive disorders of pregnancy are a major cause of maternal and fetal morbidity, with consequences later in life. Certain beta-blockers are useful for ameliorating hypertension in pregnancy and may have a protective role in endothelial dysfunction. However, some aspects of beta-blocker use in pregnancy are contentious among providers. Evidence on their safety, although well documented, is variable, and recent research reveals areas of controversy. Besides intrauterine growth restriction, other neonatal and obstetric complications remain a concern and should be explored thoroughly. Attention is necessary when treating pregnancy-associated hypertensive disorders with beta-blockers. Specific beta-blockers are considered safe in pregnancy, although the associated effects in the fetus are not clearly known and evidence is lacking for many safety outcomes, other than intrauterine growth restriction. Nevertheless, beta-blockers with specific indications in pregnancy under individualized selection and monitoring may confer substantial improvements in pregnant women with hypertension.

查看原文本刊更多论文

妊娠期β受体阻滞剂:临床更新。

综述的目的:本综述的目的是确定β受体阻滞剂对高血压孕妇的预期益处和不良反应。另一个问题是评估β受体阻滞剂对婴儿可能产生的不良影响，并就妊娠相关高血压患者β受体阻滞剂的适当选择和个体化降压治疗提供目前的共识建议。近期研究发现:妊娠期高血压疾病是孕产妇和胎儿发病的主要原因，其后果会影响到以后的生活。某些受体阻滞剂对改善妊娠期高血压有用，并可能对内皮功能障碍有保护作用。然而，β受体阻滞剂在妊娠期使用的某些方面存在争议。关于它们的安全性的证据，虽然有充分的记录，但是可变的，最近的研究揭示了有争议的领域。除了宫内生长受限，其他新生儿和产科并发症仍然是一个值得关注的问题，应该彻底探讨。当使用β受体阻滞剂治疗妊娠相关高血压疾病时，必须注意。特异性-受体阻滞剂被认为在妊娠期间是安全的，尽管其对胎儿的相关影响尚不清楚，而且除了宫内生长受限外，缺乏许多安全性结果的证据。然而，在个体化选择和监测下，妊娠期具有特定适应症的β受体阻滞剂可能会给高血压孕妇带来实质性的改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Hypertension Reports 医学-外周血管病

CiteScore

10.50

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hypertension. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as antihypertensive therapies, associated metabolic disorders, and therapeutic trials. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.